Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB102 SAD and MAD in Healthy Participants
NCT07662057Phase 1Recruiting
- Sponsor
- Arcus Biosciences
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AB102 (4 arms), sponsored by Arcus Biosciences. Primary endpoints: Adverse Events up to 49 days, Maximum observed plasma concentration up to 28 days and 8 more. Started Jul 2026; status: recruiting.
02
Drugs
AB102
Beyond the preview
Go deeper on NCT07662057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07662057.